A new trading day began on Friday, with Autolus Therapeutics plc ADR (NASDAQ: AUTL) stock price up 3.52% from the previous day of trading, before settling in for the closing price of $2.84. AUTL’s price has ranged from $2.69 to $7.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 190.29%. Meanwhile, its annual earnings per share averaged 24.87%. With a float of $236.67 million, this company’s outstanding shares have now reached $266.12 million.
The extent of productivity of a business whose workforce counts for 463 workers is very important to gauge. In terms of profitability, gross margin is 51.97%, operating margin of -1739.83%, and the pretax margin is -2172.6%.
Autolus Therapeutics plc ADR (AUTL) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Autolus Therapeutics plc ADR is 11.07%, while institutional ownership is 56.27%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.45 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.87% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Here are Autolus Therapeutics plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 13.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
The latest stats from [Autolus Therapeutics plc ADR, AUTL] show that its last 5-days average volume of 2.43 million was superior to 1.46 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 13.39%. Additionally, its Average True Range was 0.30.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 10.82%, which indicates a significant decrease from 17.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.68% in the past 14 days, which was higher than the 71.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.79, while its 200-day Moving Average is $4.43. Now, the first resistance to watch is $3.07. This is followed by the second major resistance level at $3.21. The third major resistance level sits at $3.36. If the price goes on to break the first support level at $2.78, it is likely to go to the next support level at $2.63. Assuming the price breaks the second support level, the third support level stands at $2.49.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
With a market capitalization of 782.39 million, the company has a total of 266,094K Shares Outstanding. Currently, annual sales are 1,700 K while annual income is -208,380 K. The company’s previous quarter sales were 0 K while its latest quarter income was -58,270 K.
